Variables | Values |
---|---|
Diagnosis, n | 11 PsA |
3 axSpA and psoriasis | |
Previous obstetric history, n | 3 miscarriages |
10 live births | |
Therapy pre-pregnancy, n | 4 NSAID alone |
3 SSZ ± PSL | |
8 anti-TNF-α therapy ± SSZ1 | |
1 LEF2 | |
Therapy intervention during pregnancy, n | 3 started PSL |
Therapy intervention postpartum, n | 4 given oral or intramuscular steroids |
1 restarted MTX | |
3 restarted anti-TNF-α therapy | |
Pregnancy outcomes | |
Median age at delivery, yrs | 34 |
Birth outcome | 14 live births, 2 first trimester miscarriages |
Maternal complications | None |
Mode of delivery | 8 vaginal; 2 elective, 1 emergency cesarean |
Fetal outcomes3 | |
Birth weight, kg, mean (range) | 3.2 (2.9–3.8) |
Gestation, weeks, mean (range) | 39.5 (37–42) |
Congenital anomalies | None |
↵1 Anti-TNF-α was stopped during the first trimester of pregnancy in all 8 patients.
↵2 LEF was stopped and cholestyramine washout given pre-pregnancy.
↵3 For the 11 births at UCLH. PsA: psoriatic arthritis; NSAID: nonsteroidal antiinflammatory drug; SSZ: sulfasalazine; PSL: prednisolone; anti-TNF-α: antitumor necrosis factor-α; LEF: leflunomide; UCLH: University College London Hospital; axSpA: axial spondyloarthritis; MTX: methotrexate.